ACAD - Spark Newswire

1 minute read

Acadia’s Non-Opioid Post-Operative Pain Med Flunks In Mid-Stage Study

Today, 9:02 AM

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.

ACAD

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 9:02 AM

Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.

ABIO

2 minute read

28 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:02 AM

Gainers

ACAD

6 minute read

Stocks That Hit 52-Week Highs On Thursday

By Benzinga Insights

Today, 9:02 AM

On Thursday, 75 stocks made new 52-week highs.

ABBV

2 minute read

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight

By Shanthi Rexaline

Today, 9:02 AM

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.

ACAD

3 minute read

A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision

By Lisa Levin

Today, 9:02 AM

Pre-open movers

ACAD

1 minute read

Canaccord Genuity Upgrades ACADIA Pharmaceuticals to Buy, Raises Price Target to $31

By Benzinga Newsdesk

Today, 9:02 AM

Canaccord Genuity upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Hold to Buy and raises the price target from $30 to $31.

ACAD

1 minute read

Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $37

By Benzinga Newsdesk

Today, 9:02 AM

Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $32 to $37.

ACAD

1 minute read

Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $28

By Benzinga Newsdesk

Today, 9:02 AM

Mizuho analyst Vamil Divan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $33 to $28.

ACAD

2 minute read

Earnings

ACADIA Pharmaceuticals’s Return On Capital Employed Overview

By Benzinga Insights

Today, 9:02 AM

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $130.76 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 198.08%, resulting in a loss of $43.09 million.

ACAD

Feed Symbols: ACAD